Brief: Flerie Portfolio Firm Reports Positive Bladder Cancer Data
20/05/2026 10:01
May 20 (Reuters) - Flerie AB FLERIE.ST: FLERIE'S PORTFOLIO COMPANY PROKARIUM PRESENTS POSITIVE INTERIM DATA FROM CLINICAL STUDY IN BLADDER CANCER DRUG CANDIDATE'S SAFETY PROFILE IS CONSIDERED FAVOURABLE Source text: ID:nMFNc883wB Further company coverage: FLERIE.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Flerie AB
See all newsBrief: Flerie Q3 Net Asset Value SEK 3,113 Million
Brief: Flerie Portfolio Co Reports Positive Data From Clinical Proof-Of-Mechanism Study
Brief: Flerie Writes Down Value Of Holding In Empros Pharma
Brief: Nasdaq Approves Biosergen's Delisting Application
Brief: Flerie Approves Merger Plan For Flerie And Biosergen